A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Clinical trial NCT05273554 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05273554
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-31
- Primary completion
- 2027-12-31
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.